Poolbeg Pharma PLC - London-based infectious disease focused biopharmaceutical company - Says oral vaccine programme is moving forward to encapsulation validation process. Expects validation to be completed in the second half of 2023. Back in November, Poolbeg’s consortium EncOvac received funding of €2.3 million from the Irish government to improve the manufacturing, distribution and administration of its oral vaccines. Poolbeg is collaborating with University College Dublin, Trinity College Dublin and AnaBio Technologies over three years to develop an oral vaccine candidate to a phase 1 ready state.

Poolbeg Chief Executive Officer Aidan Fitzsimons says: ‘This is a very exciting step in the development of next generation vaccines. With the EncOVac consortium, and in partnership with Poolbeg, UCD and Trinity, we can develop effective oral vaccine candidates that can provide a more accessible and efficient solution to preventing a range of infectious diseases.’

Current stock price: 8.35 pence, down 1.2%

12-month change: up 50%

Copyright 2023 Alliance News Ltd. All Rights Reserved.